Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
December 09, 2019 09:00 ET | Onconova Therapeutics, Inc.
Genomic Profiling at Study Entry in Patients with Higher Risk Myelodysplastic Syndrome (HR-MDS) Following Hypomethylating (HMA) Failure: Results From the INSPIRE Trial, including RAS and other...
Cyclacel Pharmaceuticals logo
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
December 09, 2019 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting
December 08, 2019 16:45 ET | BeiGene, LTD.
Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with...
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
December 07, 2019 14:00 ET | Autolus Therapeutics plc
AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome   Data presented at 61st American Society of Hematology Annual Meeting form...
Onconova New Letterhead Logo (002).JPG
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition
November 07, 2019 07:30 ET | Onconova Therapeutics, Inc.
Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker...
15-SORRENTO-Therapeutics-Logo-FINAL.png
 Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
November 06, 2019 19:37 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting
November 06, 2019 09:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
November 06, 2019 09:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...